[
    [
        {
            "time": "",
            "original_text": "华大基因：地中海贫血基因检测产品获SFDA批准上市",
            "features": {
                "keywords": [
                    "华大基因",
                    "地中海贫血",
                    "基因检测",
                    "SFDA",
                    "批准上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华大基因：地中海贫血基因检测产品获SFDA批准上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "太平洋健康险五周年发展回顾论坛，华大基因分享肿瘤",
            "features": {
                "keywords": [
                    "太平洋健康险",
                    "五周年",
                    "发展回顾",
                    "华大基因",
                    "肿瘤"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "保险",
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "太平洋健康险五周年发展回顾论坛，华大基因分享肿瘤",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华大基因汪建对话田朴珺：如果我们不做，中国就失去这个机会了",
            "features": {
                "keywords": [
                    "华大基因",
                    "汪建",
                    "田朴珺",
                    "中国",
                    "机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技",
                    "创新"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华大基因汪建对话田朴珺：如果我们不做，中国就失去这个机会了",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]